MeiraGTx Holdings plcMGTXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage biotechnology firm specializing in the research, development and commercialization of transformative gene therapies. Its core pipeline targets rare ophthalmic conditions, neurodegenerative disorders, and salivary gland diseases, serving patients across global markets with operations in the U.S. and European Union.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 16.40% | 12.7M | ▼ -1.60pp | 2024-08-14 |
| SANOFI | 15.80% | 12.2M | ▲ +8.40pp | 2024-08-13 |
| S.S. OR | 8.60% | 6.6M | — | 2024-10-18 |
| Adage Capital Partners, L.P. | 8.32% | 5.3M | — | 2024-02-07 |
| Adage Capital Management, L.P. | 6.77% | 5.2M | — | 2024-11-12 |
| Prosight Management, LP | 6.40% | 4.1M | ▼ -0.50pp | 2024-02-13 |
Insider Transactions
Net 90d: −$1.29M · buys $0 / sells $1.29MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-21 | Richard Giroux | CFO & COO | Sell (open market) | 56.0K | $10.22 | $572.3K |
| 2026-04-17 | PERCEPTIVE ADVISORS LLC | Director | Grant | 555.6K | $9.00 | $5.00M |
| 2026-04-07 | Stuart Naylor | CHIEF DEV. OFFICER | Sell (open market) | 27.7K | $9.36 | $258.9K |
| 2026-03-24 | Alexandria Forbes | PRESIDENT & CEO | Sell (open market) | 62.0K | $7.41 | $459.4K |
| 2026-02-21 | Zeldin Robert K | CHIEF MEDICAL OFFICER | Option exercise | 7.5K | — | — |
| 2026-02-21 | Richard Giroux | CFO & COO | Option exercise | 60.0K | — | — |
| 2026-02-21 | Stuart Naylor | CHIEF DEV. OFFICER | Option exercise | 25.0K | — | — |
| 2026-02-21 | Wollin Robert J | GENERAL COUNSEL AND SECRETARY | Option exercise | 11.3K | — | — |
| 2026-02-21 | Alexandria Forbes | PRESIDENT & CEO | Option exercise | 62.5K | — | — |
1–9 of 9